H.R. 830 · 119th Congress · Crime and Law Enforcement

SAFE Act

In committee4.8k words Introduced Jan 31, 2025 · Latest action Jan 31, 2025

How far it has goneStage 2 of 6
  1. IntroducedJan 31, 2025 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Fentanyl-related substances are currently regulated under schedule I through a temporary order issued by the Drug Enforcement Administration. The temporary order expires on March 31, 2025.

It limits mandatory minimum penalties for certain offenses involving fentanyl-related substances, establishes a process to deschedule or remove certain fentanyl-related substances that have a low potential for abuse, and allows federal courts to vacate or reduce sentences for convictions involving a fentanyl-related substance that is descheduled or moved to a schedule other than schedule I or II.

The bill establishes a new, alternative registration process for schedule I research. It also makes other changes to registration requirements for conducting research with controlled substances, including

• permitting a single registration for related research sites in certain circumstances,

• waiving the requirement for a new inspection in certain situations, and

• allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

Finally, the bill requires the Government Accountability Office to analyze the implementation and impact of permanently placing fentanyl-related substances into schedule I of the Controlled Substances Act.

Congressional Research Service · summary of “Introduced in House” version · Jan 31, 2025

Who lobbies on it

5 organizations · 21 filings · Q1 2025–Q3 2026

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 7 of 7 quarters
    “Pharmacy Benefit Manager (PBM) issues and reform. 340B. IRA implementation. H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act. Drug pricing. Most-Favored Nation (MFN) International reference pricing. H.R.5378 - Lower Costs, More Transparency Act. H.R.5376 - Share the Savings with Seniors Act. H.R.6283/S.1542…”

    Q3 2026 filing · $26.6M lobbying spend in 2026 to date, all issues

  2. Bristol-Myers Squibb Company 6 of 7 quarters
    “H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.”

    Q3 2026 filing · $7.5M lobbying spend in 2026 to date, all issues

  3. Sanofi Us Services Inc 4 of 7 quarters
    “340B; Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research…”

    Q3 2026 filing · $4.8M lobbying spend in 2026 to date, all issues

2 more organizations, every filingPROUpgrade

Organizations that named H.R. 830 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Jan 31, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Jan 31, 2025Introduced in House

What members said about it

  • Statement · Press release · Feb 6, 2025 · Cisneros D-CA

    Rep. Cisneros Statement on HALT Fentanyl Act

    Equally important, however, is ensuring that we take a holistic approach that includes access to treatment rather than performative actions that repeat the mistakes of the War on Drugs.